On October 22, 2026, the 2026 Fortune China 500 Forum was held in Chengdu. The theme of this forum is “Reinvigorating Competitiveness”. In the biomedical roundtable discussion, Huang Chen, president of Johnson & Johnson Innovative Pharmaceuticals in China, proposed that the old rules of the pharmaceutical industry were driven by scale and resources, the new rules were driven by focus and value, and the key to the turning point was shortening the innovation cycle. This judgment was echoed by the participants. The focus of industry competition is shifting from “whether there is a product” to “can solve clinical problems and advance simultaneously in the global clinical system”.

On October 22, 2026, the 2026 Fortune China 500 Forum was held in Chengdu. The theme of this forum is “Reinvigorating Competitiveness”. In the biomedical roundtable discussion, Huang Chen, president of Johnson & Johnson Innovative Pharmaceuticals in China, proposed that the old rules of the pharmaceutical industry were driven by scale and resources, the new rules were driven by focus and value, and the key to the turning point was shortening the innovation cycle. This judgment was echoed by the participants. The focus of industry competition is shifting from “whether there are any products” to “whether clinical problems can be solved and promoted simultaneously in the global clinical system”.